Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
10.3904/kjim.2007.22.1.24
- Author:
Jung Hoon LEE
1
;
Tae Nyeun KIM
;
Sun Taek CHOI
;
Byung Ik JANG
;
Kyeong Cheol SHIN
;
Sam Beom LEE
;
Young Ran SHIM
Author Information
1. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. JBI@MED.YU.AC.KR
- Publication Type:Case Report
- Keywords:
Behcet syndrome;
Tumor necrosis factor-alpha;
Infliximab
- MeSH:
Tumor Necrosis Factor-alpha/*therapeutic use;
*Treatment Outcome;
Remission Induction;
Middle Aged;
Male;
Humans;
Gastrointestinal Diseases/*drug therapy/etiology/surgery;
Gastrointestinal Agents/*therapeutic use;
Disease Progression;
Colectomy;
Behcet Syndrome/*drug therapy/physiopathology/surgery;
Antibodies, Monoclonal/*therapeutic use
- From:The Korean Journal of Internal Medicine
2007;22(1):24-27
- CountryRepublic of Korea
- Language:English
-
Abstract:
Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.
